FMC stock: Goldman Sachs cuts target for Fresenius Medical Care stock to EUR 38.00

Published on 10/20/2026 at 15:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 operating income grew 23.00 percent at constant currency. FMC stock costs EUR 39.63 on October 20, 2026, up 1.51 percent versus the Xetra close.

Goldman Sachs target update

Goldman Sachs cut its target from EUR 39.00 to EUR 38.00 on September 30, 2026.
Second-quarter operating income grew 23.00 percent at constant currency.
FMC stock costs EUR 39.63 at Lang & Schwarz on October 20, 2026 at 3:36 p.m. CEST, 1.51 percent above the Xetra close of October 19, 2026.
Third-quarter results are scheduled for November 3, 2026.

Trading-Floor mit großen Bildschirmen, die Xetra- und MDAX-Kurscharts der Gesundheitsbranche zeigen — Börsen-Editorial zeigt Trading-Floor mit Xetra- und MDAX-Charts, passend zu Fresenius Medical Care AG DE0005785802, Illustration mit AI erstellt.

Fresenius Medical Care (ISIN DE0005785802) had its target cut by Goldman Sachs from EUR 39.00 to EUR 38.00 on September 30, 2026, while the bank kept its Neutral rating, according to Finanznachrichten.de. The target is 4.12 percent below the EUR 39.63 Lang & Schwarz price. FMC stock was trading at EUR 39.63 at Lang & Schwarz on October 20, 2026 at 3:36 p.m. CEST, up 1.51 percent versus the Xetra close of October 19, 2026 at EUR 39.04.

Second-quarter income improved

The latest operating picture gives the target revision a measurable counterpoint. In the second quarter of 2026, operating income grew 23.00 percent at constant currency, while organic group revenue increased 5.00 percent. The figures came from the company earnings call published by Yahoo Finance for the second-quarter 2026 results.

Stock above the Xetra close

The October 20 move places the euro quote 1.51 percent above the previous Xetra session's EUR 39.04 close. That daily gain is smaller than the 4.12 percent gap between the Lang & Schwarz price and the Goldman Sachs target, leaving the analyst view below the current German quote.

Results date is November 3

Fresenius Medical Care's investor calendar schedules third-quarter 2026 reporting for November 3, 2026, including the business results and conference call, according to Fresenius Medical Care. The date gives investors the next company-specific checkpoint after the target revision and the second-quarter operating improvement.

What the target implies

Goldman Sachs kept its Neutral view while lowering the target by EUR 1.00. The combination of a 23.00 percent operating-income increase in the second quarter and a target below the current euro quote leaves the November report as the next test for whether profitability gains can offset the cautious analyst stance.

Price and reporting checkpoint

FMC stock was trading at EUR 39.63 at Lang & Schwarz on October 20, 2026 at 3:36 p.m. CEST, 1.51 percent above the Xetra close of October 19, 2026 at EUR 39.04. Third-quarter reporting is scheduled for November 3, 2026. The further course of trading is shown by the continuously updated real-time quote of FMC stock.